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Abstract
Introduction
The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated mor-
bidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity
and mortality compared to the non-HIV-1 infected population and this appears to be
related to end-organ diseases collectively referred to as Serious Non-AIDS Events
(SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of
human disease conditions including those that constitute SNAEs. Our study sought to
investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART
treated individuals.
Materials and Methods
A set of miRNAs was chosen based on published associations with human disease condi-
tions that constitute SNAEs. This case: control study compared 126 cases (individuals
who died whilst on therapy), and 247 matched controls (individuals who remained alive).
Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative
abundance of each miRNA in serum was measured, by RTqPCR. Associations with mor-
tality (all-cause, cardiovascular and malignancy) were assessed by logistic regression
analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer
were also assessed.
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Results
None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy
mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while
miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and
-223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR-
145 correlated with nadir CD4+ T cell count.
Discussion
No associations with mortality were found with any circulating miRNA studied. These results
cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the
major underlying diseases that contribute to mortality in participants treated for HIV-1
infection.
Introduction
While HIV-1 infection remains a critical problem, the introduction of effective anti-retroviral
drugs has been associated with dramatic decreases in both the prevalence of AIDS and the
resulting morbidity and mortality, particularly in the developed world. Current estimates sug-
gest that up to 12.9 million people are receiving some form of anti-retroviral therapy (ART)[1].
However, there is currently no cure and treatment remains life-long. People on long term ART
have increased rates of morbidity and mortality compared to uninfected individuals and these
differences appear related to a collection of end organ diseases that collectively have been
termed Serious Non-AIDS Events (SNAEs) [2–5].
The cause of these SNAEs seems to be multi-factorial. Aging [6], high-risk behaviour [7],
co-infections [8], ART toxicity [9], CD4+ T cell depletion [10, 11], microbial translocation [12]
and immune activation [13–19] all appear to contribute to SNAE pathogenesis. In the ART-
treated HIV-1 infected control arm participants in the large, well-characterized trials SMART
and ESPRIT [20–23] baseline levels of the soluble markers hs-CRP, D-dimer and IL-6 as well
as CD4+ T cell count showed strong associations with mortality [24–26]. However, the exact
mechanisms that lead to SNAEs are still unclear. How hs-CRP, D-dimer, IL-6 and CD4+ T cell
number affect their progression is equally as uncertain. While these biomarkers associate with
SNAEs the strength of these associations are lower than required for clinical utility [26]. Fur-
ther research is essential to find new biomarkers in order to strengthen the predictive power of
the established biomarkers and to provide further insight into the exact role they play in the
aetiology of SNAEs and mortality.
MicroRNAs (miRNAs) are small non-coding strands of RNA that act as important post-
transcriptional regulators of gene expression. They act upon complimentary strands of mRNA
inhibiting protein production in the cytoplasm. In addition to their cellular function, miRNAs
have also recently been found to be abundant in the circulation. These circulating miRNAs are
suspected to play an important role in intercellular communication and hold promise as non-
invasive biomarkers in a number of disease conditions [27]. The area of circulating miRNAs is
a relatively new field as it was originally thought that the high levels of RNases in the circula-
tion would prevent their existence [28]. However, miRNAs are extremely stable and able to
avoid RNase activity through two methods: first, by associating with argonaute (AGO) proteins
(>90% of circulating miRNAs appear to be AGO bound) [29, 30]; and second, by being
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secreted in exosomes [30, 31]. It is thought that the miRNAs bound to AGO are functionally
inert [30], whereas those located inside exosomes remain functional and retain the potential to
act upon mRNAs when their carrier exosomes are taken up by other cells [32]. The vast major-
ity of research into potential miRNA biomarkers has been in the cancer field [33] with a grow-
ing body of work also exploring their role in cardiovascular disease [34]. Circulating miRNAs
in the context of lentiviral infections have only been briefly explored [35–38] and it is clear that
there is a complex interplay between miRNAs and HIV-1 pathogenesis [39]. There is a growing
body of literature which supports the possibility that circulating miRNAs may provide prog-
nostic biomarkers for predicting non-AIDS related mortality in individuals on long term ART.
The primary objective of this study was to identify miRNA biomarkers predictive of all-
cause mortality in a group of ART treated HIV-1 infected individuals.
Materials and Methods
Study Details
Ethics. Samples analysed in this study were derived from participants in two international
clinical trials, SMART (NCT00027352) [23] and ESPRIT (NCT00004978) [20], run by the
INSIGHT collaboration in over 450 investigational centres between 1999 and 2009. All samples
were derived from participants who provided written informed consent to use of both their
data and of their stored samples for future laboratory research. All informed consents were
reviewed and approved by participant site ethics review committees. The ethics for SMART,
ESPRIT and this study were reviewed and approved by the UNSWHuman Research Ethics
Committee.
Study Population. Participants were selected from the control arms of the SMART [23]
and ESPRIT [20] trials. All participants in these trials were HIV-1 positive. Cases were defined
as those participants who died from any cause during follow up. Controls were defined as par-
ticipants who were known to be alive at completion of follow up and matched for age, gender,
location (continent) and randomisation date (± 3 months). To improve methodological rigour
we attempted to balance the controls on the basis of specified criteria for our cases in a ratio of
two controls for every case. This brings the comparisons closer to a randomised design by iden-
tifying patients who at the beginning of the observation have broadly similar characteristics for
a range of prognostically important covariates. When there were more than two controls per
case available two of these controls were randomly selected, however, when two matched con-
trols were not available only one was selected (5 cases). After collection, sera were double spun
and stored in sterile 1 mL aliquots at -80°C until thawed for use.
Clinical outcomes. Causes of death among cases was reviewed by an Endpoint Review
Committee and categorised using the Coding of Death in HIV (CoDE system) [40].
Measurement of hs-CRP, D-Dimer and IL-6
Hs-CRP, D-Dimer and IL-6 were measured by the Laboratory for Clinical Biochemistry
Research at the University of Vermont (Burlington) for the SMART individuals and by the
Clinical Serviced Program at the SAIC Frederick (Frederick, Maryland, USA) for the ESPRIT
individuals [24].
miRNA screen
Before performing assays on the study population the intended extraction and amplification
methodology was validated using a total miRNA screen in the serum of 4 HIV-1 infected ART
treated individuals and 4 healthy controls. RNA was extracted, reverse transcribed and pre-
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amplified according to methodologies described below. All known human miRNAs were then
measured using Taqman Array Human MicroRNA Cards A + B v3 (Life Technologies) accord-
ing to the manufacturer’s instructions.
miRNA candidate biomarkers
21 miRNAs were selected based on their reported associations with human disease conditions
associated with SNAEs in non HIV-infected populations or because they are encoded from a
virus that is known to result in chronic infection in humans. Additionally 3 miRNAs were
selected to act as reference genes and to ensure consistent RNA extraction. Full details of miR-
NAs and their associations are shown in Table 1.
Haemolysis Analysis
Free haemoglobin was measured in all of the serum samples using a Roche Diagnostics Modular
P analyser (Hoffman-La Roche. Basel, Switzerland) according to standard methodology [66].
RNA Extraction
In a 2mL RNase free screw top tube 1000ul of Trizol1 LS reagent (Life Technologies Carlsbad,
CA, USA) was added to 400μl of serum. In order to increase RNA yield and to ensure extrac-
tion of GC poor miRNAs [67], 5ul of glycogen (20ng/μl) was added. This mixture was inverted
end over end and then vortexed for 30 seconds before being incubated at room temperature for
a further 10 minutes. 3.5ul of Cel-miR-39 (1.6x108 copies/μl) (Qiagen, Venlo, Limburg, Neth-
erlands) was then added to the mixture. Following this 200μl of chloroform was added and the
mixture was shaken vigorously for 20 seconds before being incubated at RT for 15 minutes.
Afterwards the mixture was centrifuged in a Heraeus Fresco microcentrifuge (Thermo Scien-
tific, Waltham, MA USA) at 12,000g for 15 minutes at 4°C. The aqueous phase was removed
into a new 2mL tube before 1000μl of 100% isopropanol was added. The resulting mixture was
vortexed for 5 seconds and incubated at RT for 10 minutes before centrifugation at 12,000g for
8 minutes at 4°C. The supernatant was removed and 1000μl of cold 75% ethanol was added to
the pellet and the tubes were inverted 5 times. This mixture was centrifuged at 7500g for 5 min-
utes at 4°C. The supernatant was carefully removed and the pellet was allowed to air dry. The
dried pellet was eluted into 25μl of RNase free H2O and stored at -80°C.
Reverse Transcription
RNA was reverse transcribed using the Taqman MicroRNA Reverse Transcription Kit (Life
Technologies) according to manufacturer’s instructions. One reaction of the reverse transcrip-
tion mastermix for both the Taqman array cards and 384 well PCRs consisted of 6μl of a cus-
tom RT primer pool, 0.3μl of dNTPs, 3ul of reverse transcriptase, 1.5μl of 10xRT buffer, 0.19
RNase inhibitor and 1.01μl of nuclease free water. In 96 well PCR plates 12μl of the RT master-
mix was combined with 3μl of sample RNA. Samples were run on Veriti Thermocycler (Life
Technologies) for 30 minutes at 16°C followed by 30 minutes at 42°C and 5 minutes at 85°C.
The resulting cDNA was stored at -80°C.
Preamplification
A single reaction of the pre-amplification mastermix used for both Taqman array cards and 384
well PCRs consisted of 12.5μl of 2x Pre-amplification mastermix (Life Technologies) 3.75μl of
custom pre-amplification primers and 6.25ul nuclease free water. In 96 well plates 22.5μl of the
pre-amplification master-mix was combined with 2.5μl of cDNA from the RT reaction
Circulating miRNAs in ART Treated Individuals with HIV-1 Infection
PLOS ONE | DOI:10.1371/journal.pone.0139981 October 14, 2015 4 / 23
Table 1. MiRNAs selected for analysis.
miRNA Reason for Inclusion Reference
miR-16 • Reference Gene [41]
U6snRNA • Life Technologies internal calibrator
U6snRNA • Life Technologies internal calibrator
Cel-miR-39 • Spike in control for RNA extraction
miR-126 • Induces CXCL12 dependent vascular protection [32, 42–44]
• Decreased in patients with coronary artery disease
• Positively associated with myocardial infarction in the Bruneck cohort
• Decreased in type 2 Diabetes in the Bruneck cohort
miR-223 • Inversely associated with myocardial infarction in the Bruneck cohort [43, 44]
• Decreased in type 2 Diabetes in the Bruneck cohort
miR-221 • HIV tat decreases miR-221 in HUVEC cells which increases ICAM-resulting in an increase of monocyte adhesion [45–48]
• Differentially regulated in a number of cancer types including colorectal non-small cell lung cancer and prostate
cancer
miR-21 • Decreased in type 2 Diabetes in the Bruneck cohort [35, 43, 44,
49]• Increased in patients with CVD compared to aged matched non-CVD individuals while also correlating with hs-
CRP and fibrinogen
• Induces IL-6 by binding to TLR8
• Increased in circulation of macaques that developed SIV related CNS disease compared to no disease
miR-197 • Inversely associated with myocardial infarction in the Bruneck cohort [43, 44, 50]
• Decreased in type 2 Diabetes in the Bruneck cohort
• Increased levels correlate with hypertension and BMI possibly leading to dyslipidaemia in metabolic syndrome in
metabolic syndrome
miR-145 • Decreased in patients with coronary artery disease [42]
miR-155 • Decreased in patients with coronary artery disease [42, 51]
• Increased in inflammatory liver damage
miR-146a • Upregulated in type 2 diabetic patients compared to pre-diabetic and diabetes susceptible individuals [35, 51, 52]
• Increased in inflammatory liver damage
• Increased in circulation of macaques that developed severe SIV related CNS disease compared to no disease
miR-122 • Increased in inflammatory liver damage [51, 53, 54]
• Essential for HCV replication in liver cells
• Increased in hyperlipidaemia and associated with coronary artery disease
miR-200a • Increased in HCV/HIV co-infected compared to HIV mono-infected individuals [55]
miR-572 • Decreased in monocytes of chronically HIV-1 infected individuals compared to LTNPs and Healthy controls [56]
miR-31 • Down-regulated during HIV-1 infection and significantly associated with HIV-1 viral load and CD4+ T cell count in
PBMCs
[57]
miR-24 • Decreased in type 2 Diabetes in the Bruneck cohort [43, 44]
miR-29a • Upregulated in type 2 diabetic patients compared to pre-diabetic and diabetes susceptible individuals [49, 52]
• Induces IL-6 by binding to TLR8
miR-370 • Increased in hyperlipidaemia and associated with coronary artery disease [53]
miR-150 • Negatively correlated with hs-CRP in atrial fibrillation patients [58, 59]
• Increased levels associate with lymphocyte activation
Let-7e • Let-7e correlates with IL-6 in SIV infected macaques and targets IL-6 in both macaques and humans [35, 60, 61]
• Increased in hypertensive patients compared to healthy controls
miR-134 • Increased in patients with acute pulmonary embolism and a positive D-dimer ELISA [62]
EBV-miR-BART15 • Secreted, in exosomes, from infected B-cells to non-infected cells to target the miR-223 NLRP3 binding site
inhibiting IL-1B
[63]
EBV-miR-BART1-
5p
• Transported from EBV infected B cells to non-infected cells via exosomes altering CXCL11 in these cells [64]
(Continued)
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according to the manufacturer’s instructions. Samples were run on a Veriti Thermocycler (Life
Technologies) for 95°C for 10 minutes, 2 minutes at 55°C, 2 minutes at 72°C followed by 12
cycles of (15 seconds at 95°C and 4 minutes at 60°C) and finally 99.9°C for 10 minutes. The
resulting pre-amplification product was diluted 1:8 with 0.1x TE buffer and stored at -80°C.
RTqPCR
The 24 miRNAs chosen for analysis were measured, in duplicate according to manufacturer’s
instructions, using custom designed taqman array cards. Briefly 100μl of diluted pre-amplified
product was combined with 100μl of 2x Gene Expression Mastermix and added to the wells of
the Array Card. The array cards were then centrifuged for 2 x 1 minute spins at 331g using a
Heraeus Multifuge 3S-R (Thermo-Scientific) before being sealed using the Array Card Staker/
Sealer (Life Technologies). Assays were repeated for the 5 human miRNAs that showed non-
specific amplification, using the custom Taqman array cards, on 384 well PCR plates. Each
individual PCR reaction on the 384 well plates consisted of 5μl of 2x Gene expression master-
mix, 0.5μl of probe/primer mix (life Technologies), 4μl of nuclease free water and 0.5ul of the
diluted pre-amplification product. Both the array cards and the 384 well plates were run on a
Quantstudio 7 RTqPCR machine (Life Technologies). MiR-16 was run on both the array cards
and 384 well plates and acted as a reference gene.
Statistical Analysis
Power Calculations. Power calculations were conducted a priori and indicated that for
all-cause mortality, using a binary miRNA split at the median value in the control group, the
study had 80% power to detect an odds ratio of 2.0. The study was less well powered for the
analyses of cardiovascular and malignancy related mortality and these analyses are viewed as
more exploratory. The power of the analyses is best interpreted by the 95% confidence intervals
given for all effect estimates.
miRNA Quantitation. All 21 candidate biomarker miRNAs were measured in duplicate
in the serum of the cases and controls and normalised to miR-16 expression. Significant non-
specific amplification was observed for miRs -29a, -197, -572, -146a and -155 using the Taq-
man Array Cards (data not shown). Therefore, the assays for these miRNAs were repeated
using a reverse transcription and pre-amplification primer pool consisting of only the 5 failed
miRNAs primers as well as the miR-16 primers. The resulting pre-amplified cDNA was ana-
lysed by RTqPCR in 384 well plates. HCMV-miR-UL112 PCR primers were suspected to be
interacting with the human miRNA primers during the pre-amplification step, causing non-
specific amplification and were therefore excluded (data not shown). Baseline miRNA relative
abundance was measured and defined as the Ct (the point at which the reporter fluorescence
becomes greater than the threshold and is considered a real signal) of the target miRNA nor-
malised to miR-16 (Ct of miRNA of interest–CT of miR-16). These values were then summa-
rised for cases and controls as medians and interquartile ranges (IQRs). EBV-miR-BART15
and EBV-miR-BART-1-5P were only detected reliably (<33 cycles) in 5 and 12 individuals
Table 1. (Continued)
miRNA Reason for Inclusion Reference
HCMV-miR-UL112 • Increased in hypertensive patients compared to healthy controls However there is a rebuttal letter suggesting that
higher CMV-miR-UL112 may be a consequence not the cause of hypertension
[60, 65]
Unless otherwise stated all studies refer to the miRNA in question in the circulation and in humans.
doi:10.1371/journal.pone.0139981.t001
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respectively and were therefore excluded from further statistical analysis. One individual (a
control) showed no amplification in any of the miRNAs tested and was therefore excluded
from the analysis.
miRNA association with mortality (all-cause). Associations of miRNAs with all-cause
mortality were explored using conditional logistic regression analyses, matching cases with con-
trols. Initial unadjusted analyses assessed the increased odds of mortality per unit (log10)
increase in relative abundance of each miRNA. Subsequent analyses were based on splitting each
miRNA into quartiles based on the values among controls. The following analyses were per-
formed; first, unadjusted analyses assessed the odds of death in each quartile compared to the
lowest quartile as reference group; Second, analyses adjusted for age, race (white, black, other),
baseline CD4, ART and HIV (no ART, ART and HIV<400 copies/mL, ART and HIV>400 cop-
ies/mL), prior AIDS, hepatitis B or C co-infection, other risk factors (current smoker, diabetes,
blood pressure lowering drugs, lipid lowering drugs, prior CVD, total/HDL cholesterol ratio,
BMI); and third, analyses adjusted for the variables in (ii) plus CRP, d-dimer and IL-6.
miRNA association with mortality (cardiovascular and malignancy). Conditional logis-
tic regression analysis was also used to determine if miRNAs were associated with either car-
diovascular or malignancy related mortality. The odds of cardiovascular or cancer death per
log10 increase in each miRNA were calculated, both unadjusted and adjusted for age, CD4+ T
cell count, ART and HIV RNA level, and prior AIDS. These analyses were not adjusted for all
covariates because of the smaller number of events. The choice of adjustment covariates was
based on those covariates that were significant in the analyses of all-cause mortality.
miRNA correlation with established biomarkers. Correlations between the established
biomarkers (hs-CRP, D-dimer, IL-6 and CD4+ T cells) and miRNAs (normalised to miR-16)
were assessed using Spearman’s non-parametric correlation coefficient with a relationship
deemed significant with p<0.05. Levels of miRNAs and established biomarkers were then
log10 normalised and plotted on xy scatter plots using Prism (Graphpad, La Jolla, CA, USA).
In all analyses, p-values and confidence intervals are presented unadjusted for multiple
comparisons.
Results
Study Population
126 cases and 247 matched controls were identified from the control-arm participants of the
SMART [23] and ESPRIT [20] trials. Baseline characteristics of cases and controls can be
found in Table 2. Causes of death for cases are summarised in Table 3.
Sample Quality Control
In order to validate the use of miR-16 as a reference gene, the extent of haemolysis was assessed
by measuring free haemoglobin in all samples prior to analysis. Less than 8% of all samples
showed any levels of haemolysis, with 75% of these haemolysed samples exhibiting very low
levels of haemolysis (haemoglobin between 10 and 20mg/dL). Additionally, the distribution of
samples with high levels of haemoglobin level (above> 10mg/dL) was similar between the two
groups (cases: 41% of haemolysed samples; controls: 59%). Due to the relatively small numbers
of haemolysed samples and their even spread across cases and controls, it was highly unlikely
that these samples would affect downstream analysis, so no samples were excluded due to
haemolysis.
CEL-miR-39 spike in control was added to the samples prior to RNA extraction to ensure
consistent extraction. RTqPCR results showed this miRNA was expressed stably throughout all
the samples (S1 Fig) thus validating the extraction process.
Circulating miRNAs in ART Treated Individuals with HIV-1 Infection
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miRNA association with all-cause mortality
The main aim of the study was to determine if any of the individual miRNAs measured (S1
Table) showed an association with all-cause mortality in ART treated individuals. Unadjusted
logistic regression analysis failed to find any significant associations between any of the
Table 2. Baseline Characteristics for Cases and Controls.
Baseline Characteristics Control (n = 247) Case (n = 126)
Age ± SD (years) 47.29 ± 9.62 48.29 ± 10.60
Mean baseline CD4+ T cell count ± SD 584.94 ± 253.11 533.865 ± 224.37
Mean nadir CD4+ T cell count± SD 232.79 ± 172.90 207.04 ± 159.18
Mean BMI ± SD 24.84 ± 4.13 24.78 ± 5.36
Mean hs-CRP ± SD 3.97 ± 8.56 5.62 ± 8.53
Mean D-dimer ± SD 0.41 ± 0.68 0.50 ± 0.54
Mean IL-6 ± SD 2.67 ± 2.36 5.03 ± 10.11
%male 82.52 82.54
Race (%white) 69.51 73.81
Race (%black) 19.92 19.84
Race (%other) 10.57 6.35
Off ART (%) 7.72 10.32
On ART with HIV RNA 500 (%) 74.39 61.90
On ART with HIV RNA >500 (%) 17.89 27.78
HBV (% surface antigen positive) 2.44 3.97
HCV (% antibody positive) 17.48 30.95
Prior AIDS (% baseline positive) 26.02 29.37
Diabetes (% baseline positive) 4.47 8.73
Prior CVD (% baseline positive) 1.63 8.73
Lipid Lowering Drug (% baseline positive) 17.48 18.25
Blood Pressure Lowering Drug (% baseline positive) 12.6 23.02
Smoking (% smokers) 36.751 59.321
Mean total cholesterol ± SD 198.8 ± 44.571 195.2 ± 53.211
1 Details were available for the SMART study only; control n = 117, case n = 59
doi:10.1371/journal.pone.0139981.t002
Table 3. Causes of Death for the SMART and ESPRIT cohorts.
SMART ESPRIT Overall
Cause of death Number % Number % Number %
Opportunistic disease (AIDS) 3 5.1 3 4.5 6 4.8
CVD + unwitnessed/sudden death 20 33.9 24 35.8 44 35
Hepatic disease 3 5.1 10 14.9 13 10.3
Renal disease 2 3.4 0 0 2 1.6
Infection (excluding OD and hep B/C) 5 8.5 2 3 7 5.6
Non-AIDS malignancy 12 20.3 11 16.4 23 18.3
Trauma 3 5.1 6 9 9 7.1
Substance abuse/intoxication 6 10.1 4 6 10 7.9
Suicide 2 3.4 2 3 4 3.2
Other 3 5.1 5 7.4 8 6.2
Total 59 100 67 100 126 100
doi:10.1371/journal.pone.0139981.t003
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Table 4. Associations of all-causemortality with miRNA levels.
miRNA n, Median (IQR) Univariate OR (95% CI), p value
miR-126
Control 246, 3.09 (2.21, 3.69)
Case 126, 2.71 (2.25, 3.68) 0.98 (0.79, 1.20), 0.82
Let-7e
Control 245, 6.71 (5.91, 7.42)
Case 125, 6.63 (5.99, 7.47) 1.05 (0.88, 1.27), 0.57
miR-21
Control 246, 6.34 (5.34, 7.07)
Case 126, 6.04 (5.11, 6.87) 0.91 (0.77, 1.08), 0.28
miR-24
Control 246, 4.64 (3.88, 5.42)
Case 125, 4.46 (3.71, 5.16) 0.99 (0.82, 1.18), 0.88
miR-122
Control 246, 6.60 (4.91, 7.70)
Case 125, 6.05 (4.39, 7.83) 0.94 (0.86, 1.04), 0.23
miR-134
Control 246, 8.65 (7.24, 10.16)
Case 126, 8.74 (7.34, 10.41) 1.07 (0.98, 1.16), 0.15
miR-145
Control 246, 9.75 (8.23, 10.69)
Case 125, 9.68 (8.79, 10.47) 1.10 (0.97,1.26), 0.14
miR-200a
Control 218, 15.01 (13.54, 16.20)
Case 116, 14.62 (13.24, 15.93) 0.93 (0.83, 1.04), 0.18
miR-150
Control 246, 4.55 (3.25, 5.58)
Case 126, 4.48 (4.48, 3.35) 1.07 (0.94, 1.23), 0.31
miR-221
Control 246, 8.14 (6.90, 9.28)
Case 125, 8.21 (7.32, 9.08) 1.10 (0.96,1.25), 0.16
miR-223
Control 246, -0.96, (-1.79, -0.15)
Case 126, -1.02 (-2.08, -0.34) 0.97 (0.81,1.15), 0.75
miR-31
Control 175, 15.69 (14.19, 16.87)
Case 96, 15.33 (13.69, 16.88) 0.91 (0.80, 1.04), 0.17
miR-370
Control 238, 11.45 (9.90, 12.75)
Case 115, 11.28 (10.20, 12.92) 1.03 (0.94, 1.13), 0.55
miR-29a
Control 223, 5.43 (4.14, 6.58)
Case 114, 5.11 (4.22, 6.10) 93 (0.81, 1.07), 0.31
mir-146a
Control 237, 0.87 (-0.31, 2.13)
Case 120, 1.06 (-0.15, 1.90) 1.01 (0.90, 1.13), 0.91
miR-197
Control 236, 5.62 (4.23, 7.14)
(Continued)
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miRNAs analysed and all-cause mortality (Table 4). As not all miRNAs were detected in all
samples the number of cases and controls varies for each miRNA tested. Pre-specified adjusted
analyses based on miRNAs separated into quartiles also failed to find any associations between
the miRNAs tested and all-cause mortality (S2 Table). Some miRNAs reached significance
when comparing individual quartiles; however, this was always limited to a single quartile.
Overall, none of these miRNAs was associated with all-cause mortality.
miRNA association with cause-specific mortality (cardiovascular and
malignancy)
Logistic regression analyses were also performed to determine if there was any association
between miRNAs and either cardiovascular or malignancy related deaths. These two clinical
outcomes formed the majority of the deaths in the cases (35% and 18% respectively) and were
the only ones that had a large enough sample size for individual statistical analysis. However,
again, no association with mortality was found (S3 and S4 Tables).
miRNA correlation with established biomarkers
Increased levels of the inflammatory markers IL-6 and hs-CRP and the coagulation marker D-
dimer have been shown to be associated with increased morbidity and mortality in ART treated
HIV-1 infected individuals [24, 26]. However, the exact mechanism by which the inflammatory
and coagulation pathways are triggered and how these pathways associate with SNAEs is not
clear. If not predictive of the adverse outcomes themselves the miRNAs may still provide some
insight as to the mechanism by which the established biomarkers associate with SNAEs. Spear-
man’s correlations comparing hs-CRP, D-dimer and IL-6 and the individual miRNAs were
analysed. While no miRNA showed any significant correlation with hs-CRP, three miRNAs,
miR -21 (r = 0.13), -122 (r = 0.10) and -200a (r = 0.14), showed significant correlations with
IL-6 and miR-21 (r = 0.13) showed an additional correlation with D-dimer (Fig 1).
CD4+ T cell counts have also previously shown significant associations with SNAEs [10,
25]. Of the 21 miRNAs measured three, miR-31 (r = 0.14), -150 (r = 0.11)and -223 (r = 0.18),
significantly correlated with the CD4+ T cell count taken at the same time as the serum sam-
ples from which the miRNAs were measured (Fig 2). Additionally, expression of miRs -31
(r = 0.12), -150 (r = 0.10), -223 (r = 0.13) as well as miR-145 (r = 0.13) correlated with nadir
CD4+ T cell counts (S2 Fig).
Discussion
Recent research in non HIV-1 infected individuals has suggested that miRNAs are either pre-
dictive of or associated with a wide variety of human disease conditions, including those that
Table 4. (Continued)
miRNA n, Median (IQR) Univariate OR (95% CI), p value
Case 116, 5.66 (4.40, 6.60) 1.02 (0.91, 1.13), 0.78
miR-155
Control 221, 6.55 (5.48, 7.85)
Case 111, 6.63 (5.19, 7.39) 0.95 (0.86, 1.05), 0.31
miR-572
Control 202, 13.34 (10.75, 15.24)
Case 96, 13.07 (11.74, 14.46) 0.98 (0.89, 1.07), 0.62
doi:10.1371/journal.pone.0139981.t004
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contribute to the increased morbidity and mortality seen in ART treated individuals. However,
no study has explored their potential to predict mortality in ART treated HIV-1 infected indi-
viduals. As SNAEs represent a considerable burden of disease in the HIV-1 infected population
we decided to explore the associations between both all-cause mortality and SNAEs, that
resulted in death (specifically cardiovascular and malignancy related death), and a selected
panel of circulating miRNAs. What sets this study apart from the majority of other studies into
circulating miRNAs is that for every case there were carefully chosen matched controls. This is
the first example of this methodology being employed to explore the predictive potential of
miRNAs in an HIV-1 context. Importantly this study is one of few that utilises matched con-
trols in all of miRNA biomarker research. The miRNAs that were tested have been shown, in
Fig 1. miRNA Correlations with IL-6 and D-dimer.MiR-16 normalised miRNA values were plotted against levels of established SNAE biomarkers (Il-6, D-
dimer and hs-CRP). Both miRNA and biomarker levels were log transformed and correlated using the nonparametric Spearman’s Correlation co-efficient.
Data was considered significant with a p value < 0.05. MiRs -200a, -122 and -21 all showed correlation with Il-6. MiR-21 additionally showed correlation with
D-dimer. None of the miRNAs showed any correlation with hs-CRP.
doi:10.1371/journal.pone.0139981.g001
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other studies, to significantly associate with human disease conditions that contribute to
SNAEs. However, when evaluated in this set of ART treated HIV-1 infected cases and controls
they showed no associations with all-cause mortality. Additionally no associations between
miRNA and death were observed when the cardiovascular and malignant deaths were analysed
individually. This is despite many of these miRNAs showing clear associations with these two
disease conditions in the literature (Table 1) Since no one cancer dominated the malignancy
deaths it was difficult to select miRNAs that associated with general malignancy, as the major-
ity of studies into circulating miRNAs in malignant disease focused on one particular cancer
type. However, the majority of miRNAs selected have a clear association with cardiovascular
disease (Table 1). Yet it is unclear whether our results indicate that these miRNAs have no
association with cardiovascular disease in the general population as our study focused on ART-
treated HIV-1 infected individuals. The lack of association may also be due to insufficient
power of the analysis into cardiovascular related deaths.
While there were no associations with mortality a subset of the miRNAs were correlated
with biomarkers that are thought to contribute to pathogenic pathways of SNAEs including
levels of D-dimer (miR-21), IL-6 (miR-21, miR-122 and miR-200a) and CD4+ T cell count,
both nadir (miR-145, - 31, -150 and -223) and baseline (miRs -31, -150 and -223). However,
these correlations are quite weak. Moreover, it is unclear from the results in this study whether
the miRNA changes observed are happening up or downstream of the activation of the bio-
marker with which they correlate. Overall, the correlations we observed between the miRNAs
and established biomarkers are not completely discordant with results from other studies. IL-6
has been linked with circulating levels of miR-21 in the past [49] and three of the miRNAs that
associate with CD4+ T cell count in our study (miRs -31, -150 and -223) have been linked pre-
viously with HIV-1 pathogenesis [37, 38, 57, 68]. Indeed correlations between CD4+ T cell
count and mir-31 and mir-150 during HIV-1 infection have been observed previously, albeit in
cell associated miRNAs derived from PBMCs [37, 57] rather than in serum as we observed
here, providing support for the validity of the results observed here.
Limitations
While the circulating miRNAs analysed here are clearly not useful biomarkers for mortality on
ART this does not rule out all microRNAs. The miRNAs tested are only a small subset of the
few hundred miRNAs that have been found to be present in the circulation. It is possible that
other circulating or cell associated miRNAs are predictive of mortality in ART treated HIV-1
Fig 2. miRNA Correlations with baseline CD4+ T cell number.MiR-16 normalised miRNA values were plotted against CD4+ T cells measured at
baseline. Both miRNA and CD4+ T cell count were log transformed and correlated using the nonparametric Spearman’s Correlation co-efficient. Data was
considered significant with a p value < 0.05. Only MiRs -31, -150 and -223 showed significant correlation with CD4+ T cell number.
doi:10.1371/journal.pone.0139981.g002
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infected individuals. However, most approaches to analysing total miRNAs rely on the use of
small numbers of individual samples, or pool material from several individuals to establish pos-
sible associations which are then confirmed in a larger sample size. This approach allows the
measurement of a larger selection of miRNAs but may miss miRNAs that exhibit subtle yet sig-
nificant changes due to the low sample size required to make such screens financially feasible.
It was therefore decided to focus on miRNAs that already have proven associations with the
disease conditions that contribute to SNAEs (Table 1) and measure these in the cases and con-
trols chosen. Additionally as our study focused on the associations of miRNAs with mortality
(all-cause, cardiovascular and malignancy) we are unable to comment on potential miRNA
associations with individual disease conditions, such as Non-Hodgkin’s Lymphoma or CNS
disease, in HIV-1 infected individuals [35, 38]. Also, as the individuals analysed in this study
were not selected based on duration of ART, the data for which was unavailable, or HIV-1 dis-
ease stage we are unable to provide further commentary to recent studies analysing associations
between certain circulating miRNAs and HIV-1 disease progression or an individual’s response
to therapy [36, 37].
Another possible reason as to why this study showed no associations with mortality is that
our methodology does not discriminate between miRNAs bound to AGO protein and exosome
associated miRNAs. As the same miRNA could be present both bound to AGO and located in
exosomes, due to its release by different cell types, it is possible that a miRNA of one particular
source could be differentially expressed but its signal is masked by miRNAs of the alternate
source. Similarly the use of serum rather than individual cell types allows us to measure just the
equilibrium of the release and uptake or degradation of miRNA in the serum. Serum analysis
does not distinguish between miRNAs of different cellular sources which may miss perturba-
tions of production from one source if these are balanced by changes in the production or
uptake of the same miRNA by another source. However serum is easily accessible and much
more likely to provide a viable substrate for a biomarker than purified cell populations.
Conclusion
Recent studies have suggested circulating miRNAs can act as effective biomarkers for a number
of disease conditions including cardiovascular, renal, hepatic and malignancies. However when
evaluating a set of these miRNAs in a carefully chosen set of HIV-1 infected cases and controls
from two large long-term HIV trials with clear clinical outcomes (death on ART) no associa-
tions with death were observed. This is despite some of these miRNAs correlating with estab-
lished SNAE biomarkers. The associations with established biomarkers suggest that some of
the miRNAs may indeed show associations if measured closer to the events. However this asso-
ciation may not come soon enough and as an early predictor of adverse outcomes, on ART,
miRNAs do not appear to be effective biomarkers.
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